IAC/Interactivecorp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? IAC/Interactivecorp trades at $40.94 (market cap $3.05B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: IAC/Interactivecorp is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| PPLI | SLS | |
|---|---|---|
Market Cap | $3.05B | $2.27B |
Volume | 931,019 | 4,179,659 |
Sector | Media | Health |
52-Week High | $47.62 | $15.46 |
52-Week Low | $31.52 | $1.39 |
Typical Hold Time | 79 Days | — |
Enterprise Value | $3.53B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.59, down 1.7% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows mixed fundamentals: revenue declined to $2.39B in 2025 with a net loss of $104.03M, but valuation ratios appear attractive with a P/E of 6.87 and P/B of 0.59. Recent news highlights potential M&A activity, as MGM Resorts is reportedly considering a bid for PPLI, following PPLI's withdrawal of its own offer to buy MGM.
The outlook is cautiously optimistic, supported by strong analyst consensus (71.4% buy ratings) and potential upside from strategic deals. Key risks include inconsistent profitability, high debt levels, and execution challenges in a competitive media landscape. Earnings volatility remains a concern, but the low valuation and M&A speculation provide catalysts for investor interest.
No Aura AI signal available yet.
Trailing returns across standard periods
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →